The group's MagnifEye technology uses a cloud-based deep learning algorithm to automate the process. It can be quickly ‘trained’ for alternative uses such as to assess for cancer, infectious disease and fertility, as well as being deployed for plant pathogen and environmental testing.
Marketed as a business-to-business commercial product, it exists not just as a smartphone app but can be incorporated into a website or native software applications.
As well as being fast and accurate (by avoiding human error), MagnifEye is also secure and has been set to ensure results can't be tampered with. The automated system is platform agnostic.
“Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic,” said Sensyne chief executive, Lord Drayson in a statement.
“We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible."